NKTR

NEKTAR THERAPEUTICS

7 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 8

Raised $1.069 billion through equity offerings, securing a massive cash runway.

capital raise

90%

bullishMay 8

Reduced G&A expenses by 45% year-over-year.

margin expansion

60%

bearishMay 8

Continued quarterly net losses of $44.9 million.

earnings miss

40%

bullishMay 8

Received FDA Fast Track designations for rezpegaldesleukin in two indications.

regulatory action

70%

bullishMay 8

Raised $1.069 billion through equity offerings, securing a massive cash runway.

capital raise

90%

bullishMay 8

Reduced G&A expenses by 45% year-over-year.

margin expansion

60%

bearishMay 8

Continued quarterly net losses of $44.9 million.

earnings miss

40%

bullishMay 8

Received FDA Fast Track designations for rezpegaldesleukin in two indications.

regulatory action

70%

bullishMay 8

Raised $1.069 billion through equity offerings, securing a massive cash runway.

capital raise

90%

bullishMay 8

Reduced G&A expenses by 45% year-over-year.

margin expansion

60%

bearishMay 8

Continued quarterly net losses of $44.9 million.

earnings miss

40%

bullishMay 8

Received FDA Fast Track designations for rezpegaldesleukin in two indications.

regulatory action

70%

bullishMay 8

Raised $1.069 billion through equity offerings, securing a massive cash runway.

capital raise

90%

bullishMay 8

Reduced G&A expenses by 45% year-over-year.

margin expansion

60%

bearishMay 8

Continued quarterly net losses of $44.9 million.

earnings miss

40%

bullishMay 8

Received FDA Fast Track designations for rezpegaldesleukin in two indications.

regulatory action

70%

bullishMay 8

Raised $1.069 billion through equity offerings, securing a massive cash runway.

capital raise

90%

bullishMay 8

Reduced G&A expenses by 45% year-over-year.

margin expansion

60%

bearishMay 8

Continued quarterly net losses of $44.9 million.

earnings miss

40%

bullishMay 8

Received FDA Fast Track designations for rezpegaldesleukin in two indications.

regulatory action

70%

bullishMay 8

Raised $1.069 billion through equity offerings, securing a massive cash runway.

capital raise

90%

bullishMay 8

Reduced G&A expenses by 45% year-over-year.

margin expansion

60%

bearishMay 8

Continued quarterly net losses of $44.9 million.

earnings miss

40%

bullishMay 8

Received FDA Fast Track designations for rezpegaldesleukin in two indications.

regulatory action

70%

bullishMay 8

Raised $1.069 billion through equity offerings, securing a massive cash runway.

capital raise

90%

bullishMay 8

Reduced G&A expenses by 45% year-over-year.

margin expansion

60%

bearishMay 8

Continued quarterly net losses of $44.9 million.

earnings miss

40%

bullishMay 8

Received FDA Fast Track designations for rezpegaldesleukin in two indications.

regulatory action

70%

Filing History

10-QMay 8, 2026

The Q1 2026 filing reveals a company at a critical juncture, where massive capital infusion meets high-stakes clinical execution. Nektar has successfully solved its immediate liquidity crisis, but in doing so, it has concentrated its entire valuation on the success of rezpegaldesleukin. The transition to Phase 3 represents a pivotal shift from early-stage data gathering to a definitive proof-of-concept for commercial viability. Investors are now weighing the strength of a $731.6 million cash cushion against the binary risk of a Phase 3 outcome and the overhang of pending litigation. While the operational tightening and Fast Track designations provide a professional veneer of progress, the underlying reality remains that of a high-burn biotech with a single-asset dependency. The upcoming Phase 3 readouts will likely determine whether Nektar is a sustainable leader in resolution therapy or a cautionary tale of capital-intensive drug development.